Enliven Therapeutics appoints Kristine Ball to board
The company said the appointment comes ahead of a planned Phase 3 trial initiation this year.
Story updates
08:31:07 PM UTC
SquawkNews
Enliven Therapeutics appointed Kristine Ball to its Board of Directors as it prepares to initiate the pivotal Phase 3 ENABLE-2 trial of relcobatinib in previously treated CML before year-end 2026.Material DetailsContext by AI AnalystThis is a governance and readiness move as Enliven transitions tow…